Dehydroepiandrosterone sulfate as a risk factor for premature myocardial infarction: a comparative study

Korean journal of family medicine
Mohammad ShojaieArmin Akbarzadeh

Abstract

This study aimed to evaluate some of the major risk factors of myocardial infarction including dehydroepiandrosterone sulfate in patients with premature myocardial infarction (age <50 years old) and myocardial infarction (age ≥50 years). This is a parallel case-control study on 50 premature myocardial infarction patients and 50 myocardial infarction patients. We also recruited 50 matched participants for each of the two groups. Patients and their control groups were assessed for dehydroepiandrosterone sulfate serum level, diabetes mellitus, hyperlipidemia, hypertriglyceridemia, and hypertension. In addition, family history of cardiovascular disease and current smoking was recorded. Univariate and multivariate logistic regression analyses were performed to evaluate predictors of premature myocardial infarction and myocardial infarction. No significant differences were observed between the demographic data of patients and their controls. The dehydroepiandrosterone sulfate serum level was significantly higher in patients with premature myocardial infarction compared with controls. Multivariate logistic regression analysis revealed only serum dehydroepiandrosterone sulfate dehydroepiandrosterone sulfate level to be significantly as...Continue Reading

References

Jan 1, 1987·Gynecologic and Obstetric Investigation·P K HeinonenP Pystynen
Sep 17, 2003·Circulation·Kathryn M RexrodeJulie E Buring
Oct 13, 2004·The American Journal of Cardiology·Juan A FournierLuis S Díaz De La Llera
Sep 16, 2005·The New England Journal of Medicine·Jiang HePaul K Whelton
May 3, 2008·Clinical Chemistry·John H PageSusan E Hankinson
Mar 9, 2010·Pharmacology & Therapeutics·Eric Dumas de la RoqueSébastien Bonnet
Jul 9, 2010·The Journal of Clinical Endocrinology and Metabolism·Claes OhlssonAsa Tivesten
Oct 12, 2010·International Journal of Epidemiology·Shanthi MendisUNKNOWN Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial in
Apr 19, 2011·European Journal of Pharmacology·Rebeca López-MarureJoseph S Dillon
Jul 27, 2011·Calcified Tissue International·Michael A GhebreGuangju Zhai
Oct 29, 2011·The Journal of Sexual Medicine·Abdulmaged M TraishAndre T Guay
Jul 10, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Iwona GorącyAndrzej Ciechanowicz
Jul 14, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Hongxia JiaZhaoshun Jiang
Sep 1, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Marcelo Cardoso de LimaJosé Antonio Rocha Gontijo
Oct 24, 2012·The Korean Journal of Pain·Safar ZareiMohamed Amin Ghobadifar
May 25, 2013·Endocrinology and Metabolism Clinics of North America·Carolyn J Crandall, Elizabeth Barrett-Connor
May 25, 2013·Stroke; a Journal of Cerebral Circulation·Monik C JiménezKathryn M Rexrode

❮ Previous
Next ❯

Citations

Jul 28, 2019·Clinical and Experimental Pharmacology & Physiology·Ting-Ting WuXiang Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.